ERBB2 and breast cancer: Estrogen and progesterone receptors, Ki67 and HER2/neu, aka the biological profile of breast cancer, were the first examples, in the 2000s, of “new” tissue biomarkers: the expression of these phenotypical indicators allowed to select properly medical treatment and predict outcome of patients affected by breast cancer.